{"id":"vonoprazan-amoxicillin-7-days","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Diarrhea"},{"rate":"5-10","effect":"Nausea"},{"rate":"5-10","effect":"Abdominal discomfort"},{"rate":"3-5","effect":"Headache"},{"rate":"1-3","effect":"Rash (amoxicillin-related)"}]},"_chembl":null,"_fixedAt":"2026-03-30T12:09:30.992538","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Vonoprazan is a potassium-competitive acid blocker (P-CAB) that suppresses gastric acid production by inhibiting the H+/K+-ATPase pump, creating an environment hostile to acid-dependent pathogens and allowing amoxicillin to penetrate gastric tissue more effectively. Amoxicillin is a beta-lactam antibiotic that disrupts bacterial cell wall synthesis. This combination is a standard triple-therapy regimen for H. pylori eradication.","oneSentence":"Vonoprazan inhibits gastric acid secretion while amoxicillin kills Helicobacter pylori bacteria, together eradicating H. pylori infection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:15:43.085Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Helicobacter pylori infection eradication"}]},"_fixedFields":["pubmed(9)"],"trialDetails":[{"nctId":"NCT06156085","phase":"PHASE4","title":"Fourteen-Day Vonoprazan-Based Dual Therapy With Amoxicillin as First-Line Helicobacter Pylori Treatment in Comparison With Extended Sequential Therapy","status":"COMPLETED","sponsor":"Fu Jen Catholic University Hospital","startDate":"2023-11-14","conditions":"Helicobacter Pylori Infection","enrollment":337},{"nctId":"NCT07352098","phase":"NA","title":"7-day High-Dose Vonoprazan-amoxicillin Dual Therapy Versus 14-day Vonoprazan-amoxicillin Dual Therapy for H. Pylori","status":"NOT_YET_RECRUITING","sponsor":"Yueyue Li","startDate":"2026-02-01","conditions":"Helicobacter","enrollment":290},{"nctId":"NCT07333001","phase":"","title":"Efficacy and Safety of 7-day Triple Therapy Containing Amoxicillin and Tetracycline Versus 14-day Dual Therapy for Helicobacter Pylori Eradication","status":"COMPLETED","sponsor":"Yueyue Li","startDate":"2025-11-01","conditions":"HELICOBACTER PYLORI INFECTIONS","enrollment":508},{"nctId":"NCT07232095","phase":"PHASE4","title":"7-Day Vonoprazan, High-Dose Amoxicillin, and Bismuth Therapy","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-11-30","conditions":"Helicobacter Pylori","enrollment":316},{"nctId":"NCT06929962","phase":"PHASE4","title":"VA Dual Sequential Therapy","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-04-24","conditions":"Helicobacter Pylori Infection","enrollment":600},{"nctId":"NCT06576882","phase":"PHASE3","title":"7 Days vs. 14 Days of Vonoprazan-based Triple Therapy for H. Pylori Eradication","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2024-06-30","conditions":"Helicobacter Pylori Infection, Gastritis, Vonoprazan","enrollment":326},{"nctId":"NCT06723197","phase":"PHASE4","title":"Efficacy of Different Durations of Dual and Quadruple Regimens for Helicobacter Pylori Eradication","status":"RECRUITING","sponsor":"Shandong University","startDate":"2024-12-10","conditions":"HELICOBACTER PYLORI INFECTIONS","enrollment":330},{"nctId":"NCT06299605","phase":"NA","title":"Triple Versus Quadruple Therapy for the Eradication of Helicobacter Pylori","status":"ENROLLING_BY_INVITATION","sponsor":"Shandong University","startDate":"2024-11-27","conditions":"Helicobacter Pylori Infection","enrollment":375},{"nctId":"NCT06168214","phase":"PHASE4","title":"Standard or Short-course Vonoprazan Non-bismuth Triple Therapy or High-dose Dual Therapy Versus Rabeprazole-bismuth Quadruple Therapy for Primary Helicobacter Pylori Eradication","status":"RECRUITING","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2023-09-04","conditions":"the Eradication Rates of Helicobacter Pylori","enrollment":1404},{"nctId":"NCT05371249","phase":"PHASE4","title":"Vonoprazan-Based Triple Therapy in Comparison With Extended Sequential Therapy","status":"UNKNOWN","sponsor":"Fu Jen Catholic University Hospital","startDate":"2021-12-01","conditions":"Helicobacter Pylori","enrollment":628},{"nctId":"NCT05658055","phase":"PHASE4","title":"The Effect of Probiotics on Gut Microbiotain After Helicobacter Pylori Eradication","status":"UNKNOWN","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2023-06-01","conditions":"Helicobacter Pylori Infection, Infections, Intestinal Bacteria Flora Disturbance","enrollment":100},{"nctId":"NCT05345210","phase":"PHASE4","title":"Vonoprazan Hp Dual or Triple Eradication Regimes","status":"UNKNOWN","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2022-04-25","conditions":"Helicobacter Pylori","enrollment":500},{"nctId":"NCT05191888","phase":"PHASE4","title":"14-day PCAB-based High-dose Dual Therapy and14-day PCAB-based Triple Therapy vs 14-day PPI-based Reverse Hybrid Therapy","status":"UNKNOWN","sponsor":"Kaohsiung Medical University","startDate":"2021-08-06","conditions":"Helicobacter Pylori Eradication","enrollment":906},{"nctId":"NCT03908619","phase":"PHASE4","title":"A RCT of Triple Therapy With Proton Pump Inhibitor vs Vonoprazan for Helicobacter Pylori Gastritis","status":"UNKNOWN","sponsor":"Changi General Hospital","startDate":"2019-04-16","conditions":"Helicobacter Pylori Infection","enrollment":252},{"nctId":"NCT03219723","phase":"","title":"Drug Use Surveillance of Takecab for \"Supplement to Helicobacter Pylori Eradication\"","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-09-01","conditions":"Gastric/Duodenal Ulcer, Gastric MALT Lymphoma, Idiopathic Thrombocytopenic Purpura, or H. Pylori Gastritis, and Other","enrollment":560}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"recentPublications":[],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Vonoprazan+amoxicillin 7 days","genericName":"Vonoprazan+amoxicillin 7 days","companyName":"Xijing Hospital of Digestive Diseases","companyId":"xijing-hospital-of-digestive-diseases","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vonoprazan inhibits gastric acid secretion while amoxicillin kills Helicobacter pylori bacteria, together eradicating H. pylori infection. Used for Helicobacter pylori infection eradication.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}